On October 9, 2025 Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, reported that new data from the company’s ongoing Phase 1/2 clinical trial of its first-in-class transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, will be featured in an oral presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2025 (Press release, Vivace Therapeutics, OCT 9, 2025, View Source [SID1234656543]). Timothy A. Yap, M.D., Ph.D., Head of Clinical Development in the Therapeutics Discovery Division at the University of Texas, M.D. Anderson Cancer Center, will deliver the oral presentation at the conference, which is being held October 17-21, 2025, in Berlin, Germany.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the oral presentation are as follows:
Presentation #920O:
Title: Safety and efficacy of first-in-class, YAP/TEAD inhibitor, VT3989 in refractory pleural and non-pleural mesothelioma: A Phase I/II study
Presenting Author: Timothy A. Yap, M.D., Ph.D., University of Texas, M.D. Anderson Cancer Center
Session: Proffered Paper Session: Mesothelioma and thymic tumours: Targeting and breaking through
Session Date/Time: Sunday, October 19, 2025, 4:30 – 6:00 p.m. Central European Summer Time (CEST)
Presentation Date/Time: Sunday, October 19, 2025, 4:40 – 4:50 p.m. CEST
Location: Hanover Auditorium – Hall 7.2c
Previously reported initial results from the Phase 1/2 trial demonstrated VT3989 to be well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. The study (View Source) is a multi-center, open label trial designed to evaluate the safety, tolerability, pharmacokinetics (PK) and biological activity of VT3989 in patients with refractory metastatic solid tumors, including refractory non-pleural and pleural malignant mesothelioma. The study included both a dose escalation and a dose expansion phase.